CN109562137A - 用于治疗与异常炎性反应有关的病况的方法和组合物 - Google Patents

用于治疗与异常炎性反应有关的病况的方法和组合物 Download PDF

Info

Publication number
CN109562137A
CN109562137A CN201680063216.XA CN201680063216A CN109562137A CN 109562137 A CN109562137 A CN 109562137A CN 201680063216 A CN201680063216 A CN 201680063216A CN 109562137 A CN109562137 A CN 109562137A
Authority
CN
China
Prior art keywords
agent
cd62l
pharmaceutically acceptable
cells
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680063216.XA
Other languages
English (en)
Chinese (zh)
Inventor
G.D.格利克
L.弗朗彻
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Entero Therapeutics Inc
Original Assignee
First Wave Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by First Wave Biopharma Inc filed Critical First Wave Biopharma Inc
Publication of CN109562137A publication Critical patent/CN109562137A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201680063216.XA 2015-09-01 2016-09-01 用于治疗与异常炎性反应有关的病况的方法和组合物 Pending CN109562137A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562213016P 2015-09-01 2015-09-01
US62/213016 2015-09-01
US201562241508P 2015-10-14 2015-10-14
US62/241508 2015-10-14
PCT/US2016/050012 WO2017040864A1 (en) 2015-09-01 2016-09-01 Methods and compositions for treating conditions associated with an abnormal inflammatory responses

Publications (1)

Publication Number Publication Date
CN109562137A true CN109562137A (zh) 2019-04-02

Family

ID=58097295

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680063216.XA Pending CN109562137A (zh) 2015-09-01 2016-09-01 用于治疗与异常炎性反应有关的病况的方法和组合物

Country Status (21)

Country Link
US (11) US10292951B2 (enExample)
EP (1) EP3344274A4 (enExample)
JP (2) JP6955648B2 (enExample)
KR (1) KR20180080189A (enExample)
CN (1) CN109562137A (enExample)
AU (2) AU2016315852B2 (enExample)
BR (1) BR112018004069A2 (enExample)
CA (1) CA2997136A1 (enExample)
CL (1) CL2021000622A1 (enExample)
CO (1) CO2018003465A2 (enExample)
CR (1) CR20180185A (enExample)
EA (1) EA201890618A1 (enExample)
HK (1) HK1258048A1 (enExample)
IL (1) IL257801A (enExample)
MX (3) MX2018002586A (enExample)
PE (1) PE20181295A1 (enExample)
PH (1) PH12018500448A1 (enExample)
SG (1) SG10201914118SA (enExample)
TN (1) TN2018000069A1 (enExample)
UA (1) UA125747C2 (enExample)
WO (1) WO2017040864A1 (enExample)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108472245A (zh) * 2015-11-04 2018-08-31 因赛特公司 用于吲哚胺2,3-双加氧酶抑制及其适应症的药物组合物和方法
CN111122523A (zh) * 2019-12-06 2020-05-08 山西大学 一种快速识别Ag+和Cys的三相输出功能的分子逻辑门及其构建方法
CN111650307A (zh) * 2020-07-13 2020-09-11 重庆医药高等专科学校 一种同时对酒中解热镇痛类药品非法添加物定性定量检测的方法及应用
WO2020220170A1 (zh) * 2019-04-28 2020-11-05 深圳市中医院 氯硝柳胺乙醇胺盐在制备治疗系统性红斑狼疮及其并发症的药物中的应用
CN111920824A (zh) * 2020-09-11 2020-11-13 余朝权 一种治疗伤口的中药组合物
CN112007036A (zh) * 2019-05-29 2020-12-01 百岳特生物科技(上海)有限公司 化合物及其组合物用于制备缓解肺部细胞发炎活性的医药品的用途
CN112341397A (zh) * 2019-08-09 2021-02-09 成都苑东生物制药股份有限公司 新型吡嗪类衍生物或盐、异构体、其制备方法及用途
CN112826795A (zh) * 2021-03-23 2021-05-25 重庆医科大学 一种载汉防己甲素脂质体制剂及其制备方法和应用
US11192868B2 (en) 2005-05-10 2021-12-07 Incyte Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
WO2021243932A1 (zh) * 2020-06-03 2021-12-09 江苏靶标生物医药研究所有限公司 一种磷脂酰丝氨酸在制备治疗炎症性肠病药物中的应用
US11207302B2 (en) 2008-07-08 2021-12-28 Incyte Corporation 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
CN113908154A (zh) * 2021-11-29 2022-01-11 中国药科大学 硝唑尼特及其体内代谢物替唑尼特在抗银屑病及银屑病样皮肤炎症中的应用
CN114134195A (zh) * 2021-11-03 2022-03-04 南方科技大学 预防前列腺癌的药剂的筛选方法、硝唑尼特在制药中的应用
CN114246852A (zh) * 2020-09-21 2022-03-29 暨南大学 一种药物组合物在心脑血管疾病中的应用
CN114340630A (zh) * 2019-09-03 2022-04-12 方电力有限公司 用于预防和治疗乳糜泻的瑞巴派特
CN114393662A (zh) * 2021-12-21 2022-04-26 凭祥青山中密度纤维板有限公司 一种环保中密度纤维板的制备方法
CN114652734A (zh) * 2022-03-31 2022-06-24 李红梦 一种祛痘的药物组合物及其制备方法
CN114667152A (zh) * 2019-11-01 2022-06-24 首尔大学校产学协力团 免疫活性改善用组合物及其方法
CN114767871A (zh) * 2022-04-19 2022-07-22 中国工程物理研究院机械制造工艺研究所 介孔硅载药体系及制备方法和介孔硅载药
CN114796135A (zh) * 2022-03-29 2022-07-29 海南久常制药有限公司 一种硫糖铝口服制剂及其制备方法
CN115739028A (zh) * 2022-11-26 2023-03-07 西南政法大学 一种精神活性物质吸附剂及其应用
CN116036289A (zh) * 2023-02-03 2023-05-02 中国药科大学 一种增强铁死亡治疗效果的纳米制剂及其制备方法和应用
CN116077424A (zh) * 2023-02-17 2023-05-09 重庆大学 一种多功能仿生水凝胶及其制备方法和应用
CN116209432A (zh) * 2020-08-14 2023-06-02 梅约医学教育与研究基金会 组织消融方法和材料
CN116322669A (zh) * 2020-07-23 2023-06-23 普渡研究基金会 治疗sars-cov-2、其它病毒性疾病和癌症的ohpp配制的氯硝柳胺
CN116531366A (zh) * 2023-05-23 2023-08-04 新乡医学院 罗替戈汀的药物新用途
CN116917267A (zh) * 2021-01-28 2023-10-20 Imd制药公司 包含卡莫司他及氯硝柳胺的共晶、包含其的药物组合物及其制备方法
CN117045657A (zh) * 2022-05-12 2023-11-14 广州嘉越医药科技有限公司 一种药物组合及其应用
CN117899225A (zh) * 2024-01-19 2024-04-19 芮城绿曼生物药业有限公司 一种增强免疫力的兽用抗菌注射剂、制备方法及应用
CN119700664A (zh) * 2025-02-28 2025-03-28 山东新时代药业有限公司 含有活性成分琥珀酸普芦卡必利的注射液及其制备方法
CN120204184A (zh) * 2025-02-17 2025-06-27 深圳市第三人民医院(深圳市肝病研究所) 阿米替林和/或其衍生物的应用、结核分枝杆菌抑制剂和药物组合物

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE044653T2 (hu) 2009-07-22 2019-11-28 PureTech Health LLC Készítmények olyan rendellenességek kezelésére, amelyek muszkarin-receptor aktiválással enyhíthetõk
EP3338783B1 (en) 2014-09-12 2024-01-24 UNION therapeutics A/S Antibacterial use of halogenated salicylanilides
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
CN104880428B (zh) * 2015-06-23 2016-07-06 山西振东安特生物制药有限公司 一种胶体果胶铋或含胶体果胶铋制剂中铋含量的测定方法
AU2016315852B2 (en) 2015-09-01 2023-06-15 First Wave Bio, Inc. Methods and compositions for treating conditions associated with an abnormal inflammatory responses
GB201604484D0 (en) 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
US11278551B2 (en) 2017-03-15 2022-03-22 Georgetown University Treating cancer with a CCK receptor inhibitor and an immune checkpoint inhibitor
WO2018173069A1 (en) * 2017-03-21 2018-09-27 Novalead Pharma Inc. Therapeutic agent for phosphodiesterase inhibition and its related disorders
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
KR102459936B1 (ko) * 2017-10-13 2022-10-27 주식회사 엘지생활건강 알칸닌을 포함하는 구강질환 예방 또는 치료용 조성물
WO2019126739A1 (en) 2017-12-21 2019-06-27 Shepherd Therapeutics, Inc. Pyrvinium pamoate anti-cancer therapies
EP3773579A4 (en) 2018-03-26 2022-03-09 Clear Creek Bio, Inc. COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
US20200023003A1 (en) 2018-07-03 2020-01-23 Fennec Pharmaceuticals Inc. Formulations of anhydrous sodium thiosulfate
IL261670B (en) * 2018-09-06 2019-06-30 Tudu Holdings Ltd A preparation that includes magnesium and its uses
CN109180600A (zh) * 2018-09-21 2019-01-11 五邑大学 一种麝香草酚类似物及其应用
BR112021005802B1 (pt) 2018-09-28 2022-02-15 Karuna Therapeutics, Inc Composição farmacêutica oral
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP3639822A1 (en) * 2018-10-15 2020-04-22 Universität Regensburg Compound for use in the treatment of a disease characterized by dysregulated mucus production and/or secretion
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
US20210317215A1 (en) * 2018-10-31 2021-10-14 Merck Sharp & Dohme Corp. Anti-human pd-1 antibody crystals and methods of use thereof
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
JP2022527054A (ja) * 2019-03-22 2022-05-30 マンカインド コーポレイション 吸入可能な乾燥粉末
US20220193028A1 (en) * 2019-04-18 2022-06-23 Prevep Llc Therapeutic combinations, liquid pharmaceutical compositions, kits for their preparation, and methods of their use
CN110200935B (zh) * 2019-06-03 2021-03-02 浙江得恩德制药股份有限公司 一种胶体果胶铋胶囊及其制备工艺
EP3998063A4 (en) * 2019-07-08 2023-03-15 MORESCO Corporation Compositions for preparing microemulsion, microemulsion, method for producing composition and microemulsion, and use of microemulsion
US20210114973A1 (en) * 2019-10-18 2021-04-22 First Wave Bio, Inc. Pharmaceutical formulations
WO2021142238A1 (en) 2020-01-10 2021-07-15 First Wave Bio, Inc. Deuterated niclosamide
WO2021142240A1 (en) 2020-01-10 2021-07-15 First Wave Bio, Inc. Compositions comprising niclosamide for use in treating conditions associated with an abnormal inflammatory response
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
WO2021188564A1 (en) 2020-03-16 2021-09-23 First Wave Bio, Inc. Methods of treating covid-19 with a niclosamide compound
TW202200197A (zh) * 2020-03-19 2022-01-01 英商崔澤爾有限公司 溫度反應型病毒儲存系統
US20210290651A1 (en) 2020-03-20 2021-09-23 Clear Creek Bio, Inc. Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
CN112914547A (zh) * 2020-03-22 2021-06-08 复旦大学附属华山医院 内源性神经干细胞磁共振无创性示踪技术体系及建立方法
IL296909A (en) * 2020-04-01 2022-12-01 Union Therapeutics As Formulation
US11045434B1 (en) * 2020-04-01 2021-06-29 UNION therapeutics A/S Niclosamide formulations for treating disease
US20210346324A1 (en) * 2020-05-05 2021-11-11 NeuroBo Therapeutics, Inc. Niclosamide Formulations and Methods of Use
AU2021270856A1 (en) * 2020-05-13 2022-12-08 The Regents Of The University Of California Thiol-containing compounds for use in treating coronavirus
WO2021255218A1 (en) * 2020-06-19 2021-12-23 Charité - Universitätsmedizin Berlin A pharmaceutical combination comprising an anti-viral protonophore and a serine protease inhibitor
US20220080020A1 (en) * 2020-08-22 2022-03-17 Luc Montagnier Compositions and methods for reducing the transmissivity of illnesses using an oral delivery system
KR102636847B1 (ko) 2020-09-18 2024-02-19 경북대학교 산학협력단 티아민 유도체를 포함하는 이식편대숙주질환 예방 또는 치료용 약학적 조성물
KR102378590B1 (ko) * 2020-09-28 2022-03-24 (주)위바이오트리 난용성 약물을 포함하는 금속 (수)산화물 복합체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
WO2022093871A1 (en) * 2020-10-26 2022-05-05 The Regents Of The University Of California Sars-c0v-2 inactivation by ethacridine
CN112342028B (zh) * 2020-10-28 2021-07-09 中铁建华南建设(广州)高科技产业有限公司 盾构分散剂及其制备方法和应用
KR20220059436A (ko) * 2020-11-02 2022-05-10 (주)아이엠디팜 신규한 공결정, 이를 포함하는 약학 조성물 및 이의 제조 방법
CN112526032B (zh) * 2020-12-28 2022-05-17 北京金城泰尔制药有限公司 聚甲酚磺醛的检测方法
WO2022147499A1 (en) * 2021-01-04 2022-07-07 Neurobo Pharmaceuticals, Inc. Method of treating viral infections with a combination of niclosamide and gemcabene
JP7504304B2 (ja) 2021-01-19 2024-06-21 エリモス・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニー コロナウイルス抗ウイルス剤としてのテラメプロコールおよびノルジヒドログアイアレチン酸(ndga)誘導体
US20220304959A1 (en) * 2021-03-26 2022-09-29 First Wave Biopharma Treatment of long haulers syndrome with niclosamide
CN113368064B (zh) * 2021-06-08 2022-06-28 吉林津升制药有限公司 一种烟酸冻干粉及其制备方法
US20230203604A1 (en) * 2021-11-23 2023-06-29 nference, inc. Detection of covid-19 associated cardiac injury and vaccine-associated myocarditis
JP2025518339A (ja) * 2022-01-31 2025-06-12 リビオネックス・インコーポレイテッド 鉄キレート化のための新規液体製剤
EP4486448A1 (en) 2022-03-04 2025-01-08 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
WO2024029639A1 (ko) * 2022-08-02 2024-02-08 제이투에이치바이오텍 주식회사 3성분 프로드럭, 이의 약학적 조성물 및 의약 용도
CN115494231A (zh) * 2022-09-02 2022-12-20 武汉三鹰生物技术有限公司 一种蛋白酶抑制剂混合物及其制备方法与应用
WO2024182078A1 (en) * 2023-02-28 2024-09-06 Verté Therapeutics, Llc Veterinary transdermal gel comprising ondansetron, and related methods
CN116139116A (zh) * 2023-03-30 2023-05-23 中南大学湘雅医院 氯硝柳胺在抑制急性肝衰竭中的应用
WO2025037323A1 (en) * 2023-08-12 2025-02-20 Pavan Kumar Kothapuvari Pharmaceutical compositions for treatment of dry eye disease and associated disorders
WO2025216846A1 (en) * 2024-04-12 2025-10-16 Advancion Corporation Metalworking fluid compositions including 3-amino-2-butanol and uses thereof
CN119055625B (zh) * 2024-07-23 2025-09-09 湖北工业大学 Tiratricol在制备抗ADV7病毒药物中的应用
CN120713881B (zh) * 2025-08-21 2025-12-05 南方科技大学 氯硝柳胺在治疗器官移植排斥反应中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102861014A (zh) * 2012-10-16 2013-01-09 天津必佳药业集团有限公司 一种畜禽用抗蠕虫病复方氯硝柳胺片及其制备方法
WO2014138881A1 (en) * 2013-03-12 2014-09-18 Patheon, Inc. Drug delivery system

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3079297A (en) 1960-05-31 1963-02-26 Bayer Ag Method of combating gastropods
US3927195A (en) * 1974-01-31 1975-12-16 Lilly Industries Ltd Production of capsules
FR2505798B1 (fr) 1981-05-14 1986-07-25 Pari Symac Perfectionnement aux dispositifs comportant un ressort helicoidal utilise comme organe de transfert, d'extraction, de dosage ou de melange
NZ223200A (en) 1988-01-15 1989-01-06 Ancare Distributors Anthelmintic compositions containing 2',5-dicloro-4'-nitrosalicylanilide and non aqueous carrier
DE4005528C2 (de) 1990-02-22 1998-01-15 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für Medien
US5280784A (en) 1990-09-19 1994-01-25 Paul Ritzau Pari-Werk Gmbh Device in particular and inhalating device for treating the lung and the respiratory tracts
EP0504459B1 (de) 1991-03-21 1996-06-05 PAUL RITZAU PARI-WERK GmbH Vernebler insbesondere zur Anwendung in Geräten für die Inhalationstherapie
EP0540775B1 (de) 1991-11-07 1997-07-23 PAUL RITZAU PARI-WERK GmbH Vernebler insbesondere zur Anwendung in Geräten für die Inhalationstherapie
EP0540774B1 (de) 1991-11-07 1995-05-03 PAUL RITZAU PARI-WERK GmbH Flüssigkeitszerstäubervorrichtung
DE4225928A1 (de) 1992-08-05 1994-02-10 Ritzau Pari Werk Gmbh Paul Zerstäubervorrichtung mit Heizeinrichtung
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
DE4310575C1 (de) 1993-03-31 1994-09-15 Ritzau Pari Werk Gmbh Paul Vorrichtung zum Erzeugen von Aerosolpulsen
ES2120471T3 (es) 1993-12-17 1998-11-01 Pari Gmbh Spezialisten Fuer Effektive Inhalation Boquilla de pulverizacion.
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US6000394A (en) 1994-10-26 1999-12-14 Paul Rizau Pari-Werk Gmbh Generation of an aerosol of an exact dose
US5663155A (en) * 1994-11-30 1997-09-02 The University Hospital Compositions for the treatment of parasitic infections
DE19520622C2 (de) 1995-06-06 2003-05-15 Pari Gmbh Vorrichtung zum Vernebeln von Fluiden
DE19602628C2 (de) 1996-01-25 2000-06-29 Pari Gmbh Vernebler
EP0821970A1 (en) 1996-08-02 1998-02-04 Edward Henri Charles Verhaeren Carrier composition for influencing the tight junction permeability
US6503881B2 (en) 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
DE19734022C2 (de) 1997-08-06 2000-06-21 Pari Gmbh Inhalationstherapiegerät mit einem Ventil zur Begrenzung des Inspirationsflusses
US5905090A (en) 1998-04-29 1999-05-18 Italfarmaco S.P.A. Analogues of the active metabolite of leflunomide
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
DE19827228C2 (de) 1998-06-18 2000-07-13 Pari Gmbh Flüssigkeitszerstäubervorrichtung
AU750313B2 (en) 1998-07-27 2002-07-18 St. Jude Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
DE19962110C2 (de) 1999-12-22 2003-06-12 Pari Gmbh Inhalationsvernebler mit einstückigem Ventilelement
JP2004506609A (ja) * 2000-05-26 2004-03-04 ノボ ノルディスク アクティーゼルスカブ 新たなる医薬組成物及びその調製の為の方法
CN100370975C (zh) 2000-12-18 2008-02-27 株式会社医药分子设计研究所 炎症性细胞因子产生游离抑制剂
EP1344525A4 (en) 2000-12-22 2005-05-25 Ishihara Sangyo Kaisha ANILINE DERIVATIVES OR ITS SALTS AND CYTOKINE PRODUCTION INHIBITORS CONTAINING THEM
JP2004517699A (ja) 2001-01-30 2004-06-17 ボード オブ リージェンツ ユニバーシティ オブ テキサス システム 液体中への噴霧凍結によるナノ粒子およびミクロ粒子の製造方法
US20040022861A1 (en) 2001-01-30 2004-02-05 Williams Robert O. Process for production of nanoparticles and microparticles by spray freezing into liquid
US20040071757A1 (en) 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
WO2004006906A2 (en) 2002-07-15 2004-01-22 Combinatorx, Incorporated Methods for the treatment of neoplasms
CA2513006A1 (en) 2003-01-15 2004-08-05 Dow Global Technologies Inc. Drug particles obtained by freezing onto a cold surface
US7544712B1 (en) 2003-05-28 2009-06-09 National Health Research Insitutes Treatment of coronavirus infection
US20050123571A1 (en) * 2003-06-06 2005-06-09 Rossini Aldo A. Modulation of apoptosis
US7249224B2 (en) 2003-08-05 2007-07-24 Newisys, Inc. Methods and apparatus for providing early responses from a remote data cache
DE10340277B4 (de) 2003-08-29 2006-11-23 Bio-Gate Bioinnovative Materials Gmbh Körperpflegemittel mit Silber-Agglomeraten
CA2572638A1 (en) 2004-07-07 2006-02-09 Dana-Farber Cancer Institute, Inc. Methods and compositions for treating obesity
CN1626506A (zh) 2004-08-10 2005-06-15 李志良 高纯度、高收率氯硝柳胺的制备
EP1789018A1 (en) 2004-08-27 2007-05-30 The Dow Chemical Company Enhanced delivery of drug compositions to treat life threatening infections
JP2008540487A (ja) 2005-05-11 2008-11-20 ノボ ノルディスク アクティーゼルスカブ 肥満症の治療に有用な新規ハロアルキルスルホン置換化合物
CN101180268A (zh) 2005-05-23 2008-05-14 诺和诺德公司 新颖的卤代烷氧基-取代的水杨酰基苯胺
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
WO2008021088A2 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
US9044391B2 (en) 2007-01-10 2015-06-02 Board Of Regents, The University Of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
JP5658031B2 (ja) 2007-06-22 2015-01-21 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 薄膜凍結による安定したサブミクロンのペプチド又はタンパク質粒子の形成
US8262657B2 (en) 2007-08-16 2012-09-11 Nutek Orthopaedics, Inc. External fixation apparatus with adjustable pin clamping means and convergent bone pins
EP2230932B1 (en) 2008-01-10 2017-03-29 Evonik Röhm GmbH Coated pharmaceutical or nutraceutical preparation with enhanced active substance release in the colon
NO2252275T3 (enExample) 2008-02-13 2018-04-28
EP2123626A1 (en) 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
AU2009307753A1 (en) 2008-10-22 2010-04-29 Metaproteomics, Llc Novel mitochondrial uncoupling methods and compositions for enhancing adipocyte thermogenesis
CU23701A1 (es) 2008-12-29 2011-09-21 Ct Ingenieria Genetica Biotech Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i
US9023877B2 (en) 2009-06-26 2015-05-05 Romark Laboratories L.C. Compounds and methods for treating influenza
CN101601670B (zh) 2009-06-30 2014-06-04 青岛蔚蓝生物股份有限公司 一种宠物用复方氯硝柳胺驱虫片剂及其制备方法
KR100990110B1 (ko) 2009-08-18 2010-10-29 엘지전자 주식회사 태양 전지
WO2011035321A1 (en) 2009-09-21 2011-03-24 Duke University Treatment of wnt/frizzled-related diseases
US9206394B2 (en) 2010-02-03 2015-12-08 The University Of Tokyo Method for reconstructing immune function using pluripotent stem cells
GB201015079D0 (en) 2010-09-10 2010-10-27 Helperby Therapeutics Ltd Novel use
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US20130231312A1 (en) 2010-11-16 2013-09-05 Shengkan Jin Treatment of type ii diabetes and diabetes-associated diseases with safe chemical mitochondrial uncouplers
US20140294957A1 (en) 2011-04-18 2014-10-02 Maxdelbruck-Centrum Fur Molekulare Medizin Niclosamide for the treatment of cancer metastasis
WO2012154944A2 (en) 2011-05-10 2012-11-15 Stc.Unm Methods of treating autophagy-associated disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits
WO2013012662A2 (en) * 2011-07-15 2013-01-24 S.L.A. Pharma Ag Pharmaceutical compositions for rectal administration
KR102200176B1 (ko) 2012-05-08 2021-01-11 에어로믹스, 인코포레이티드 신규 방법
WO2014023329A1 (en) 2012-08-06 2014-02-13 Life And Brain Gmbh Niclosamide and its derivatives for use in the treatment of solid tumors
CN103891720B (zh) * 2012-12-27 2016-02-17 陕西汤普森生物科技有限公司 一种含有螺枯威的复配杀螺组合物
JP6513576B2 (ja) 2013-01-14 2019-05-15 ヘルス クリニックス リミテッド 抗がん剤および使用
SMT201900021T1 (it) 2013-04-23 2019-02-28 Zx Pharma Llc Composizione gastroresistente a base di multiparticolato con sottorivestimento proteinaceo
US9669036B2 (en) 2013-05-14 2017-06-06 The University Of Chicago Modulation of reactivation of a latent virus
US20160136123A1 (en) * 2013-06-14 2016-05-19 Vojo P. Deretic Treatment of autophagy-related disorders
WO2015017755A1 (en) * 2013-08-02 2015-02-05 The Regents Of The University Of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
CN105899223A (zh) 2013-10-28 2016-08-24 加利福尼亚大学董事会 转移性前列腺癌的治疗
NZ722927A (en) 2014-01-10 2022-07-29 Avalyn Pharma Inc Aerosol pirfenidone and pyridone analog compounds and uses thereof
CN103751854B (zh) 2014-01-20 2015-08-26 瞿介明 抗菌医用导管
PT3590962T (pt) 2014-10-23 2021-12-15 Singh Molecular Medicine Llc Anticorpos de domínio único dirigidos contra antigénios intracelulares
AR102537A1 (es) 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
JP6047203B2 (ja) 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および/または治療のための宿主防御タンパク質(hdp)模倣薬
US9566399B1 (en) 2015-04-14 2017-02-14 Clempharma LLC Deep lung alveolar aerosol targeted drug delivery
AU2015393953B2 (en) 2015-05-01 2021-09-02 Board Of Regents, The University Of Texas System Multidrug brittle matrix compositions
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
CN105063018A (zh) * 2015-08-31 2015-11-18 山西大学 一种从葡萄成熟果实中提取总rna的方法
AU2016315852B2 (en) 2015-09-01 2023-06-15 First Wave Bio, Inc. Methods and compositions for treating conditions associated with an abnormal inflammatory responses
EP3168211A1 (en) 2015-11-10 2017-05-17 Westfälische Wilhelms-Universität Münster Pharmaceutical co-crystals of niclosamide
US10189797B2 (en) 2015-12-30 2019-01-29 Duke University Chemical modulators of immune checkpoints and therapeutic use
US10588864B2 (en) 2016-03-11 2020-03-17 Gateway Pharmaceuticals LLC Pharmaceutical compositions for colon-specific delivery
US11491123B2 (en) 2016-06-23 2022-11-08 Health Research, Inc. Pharmaceutical compositions with antiflaviviral activity
US20180015153A1 (en) 2016-07-16 2018-01-18 Florida State University Research Foundation, Inc. Compounds and methods for treatment and prevention of flavivirus infection
KR101928543B1 (ko) 2017-01-09 2018-12-13 사단법인 분자설계연구소 니클로사마이드를 함유하는 Axin-GSK3 단백질 결합 관련 질환 치료용 약학조성물
WO2018136559A1 (en) 2017-01-17 2018-07-26 The Regents Of The University Of California Methods for treating flaviviruses and zika infections
JP7159174B2 (ja) 2017-02-02 2022-10-24 マックマスター、ユニバーシティー 抗菌剤用増強剤としての重炭酸塩
WO2018173069A1 (en) 2017-03-21 2018-09-27 Novalead Pharma Inc. Therapeutic agent for phosphodiesterase inhibition and its related disorders
US11426543B2 (en) 2017-04-18 2022-08-30 Inspiring Pty Ltd Dry powder inhaler and flexible bag spacer device for a dry powder inhaler
WO2018205016A1 (en) 2017-05-08 2018-11-15 The Governors Of The University Of Alberta Peroxisome biomarkers in hiv disease progression and peroxisome activating drugs for hiv treatment
CA3064005C (en) 2017-05-19 2023-03-07 Pneuma Respiratory, Inc. Dry powder delivery device and methods of use
US20200405643A1 (en) 2017-09-11 2020-12-31 Board Of Regents, The University Of Texas System Drug compositions containing porous carriers made by thermal or fusion-based processes
WO2019051437A1 (en) 2017-09-11 2019-03-14 Board Of Regents, The University Of Texas System COMPOSITIONS FOR ENHANCED MEDICATION DELIVERY
EP3727418A4 (en) 2017-12-21 2021-10-27 Civitas Therapeutics, Inc. SURFACTANT FORMULATIONS FOR INHALATION
WO2019147626A1 (en) 2018-01-23 2019-08-01 The Trustees Of Columbia University In The City Of New York Activation of mitochondrial uncoupling as a therapeutic intervention
WO2019217164A1 (en) 2018-05-09 2019-11-14 Reyoung Corporation Compositions and methods for treating cancer and other diseases
US11166926B2 (en) 2018-08-08 2021-11-09 The Hospital For Sick Children Compositions and methods for protecting a host from enteric toxigenic pathogens
WO2021040337A1 (ko) 2019-08-23 2021-03-04 주식회사 대웅테라퓨틱스 니클로사마이드 지연방출 조성물 및 이의 항바이러스 용도
US20210114973A1 (en) 2019-10-18 2021-04-22 First Wave Bio, Inc. Pharmaceutical formulations
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
US11045434B1 (en) 2020-04-01 2021-06-29 UNION therapeutics A/S Niclosamide formulations for treating disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102861014A (zh) * 2012-10-16 2013-01-09 天津必佳药业集团有限公司 一种畜禽用抗蠕虫病复方氯硝柳胺片及其制备方法
WO2014138881A1 (en) * 2013-03-12 2014-09-18 Patheon, Inc. Drug delivery system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
郑鑫主编: "《家畜疾病诊断与治疗技术》", 31 March 2003, 延边人民出版社 *

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11192868B2 (en) 2005-05-10 2021-12-07 Incyte Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
US11207302B2 (en) 2008-07-08 2021-12-28 Incyte Corporation 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
CN108472245A (zh) * 2015-11-04 2018-08-31 因赛特公司 用于吲哚胺2,3-双加氧酶抑制及其适应症的药物组合物和方法
WO2020220170A1 (zh) * 2019-04-28 2020-11-05 深圳市中医院 氯硝柳胺乙醇胺盐在制备治疗系统性红斑狼疮及其并发症的药物中的应用
CN112007036A (zh) * 2019-05-29 2020-12-01 百岳特生物科技(上海)有限公司 化合物及其组合物用于制备缓解肺部细胞发炎活性的医药品的用途
CN112341397A (zh) * 2019-08-09 2021-02-09 成都苑东生物制药股份有限公司 新型吡嗪类衍生物或盐、异构体、其制备方法及用途
CN112341397B (zh) * 2019-08-09 2023-05-23 成都苑东生物制药股份有限公司 吡嗪类衍生物或盐、异构体、其制备方法及用途
CN114340630A (zh) * 2019-09-03 2022-04-12 方电力有限公司 用于预防和治疗乳糜泻的瑞巴派特
CN114340630B (zh) * 2019-09-03 2024-05-14 方电力有限公司 用于预防和治疗乳糜泻的瑞巴派特
CN114667152A (zh) * 2019-11-01 2022-06-24 首尔大学校产学协力团 免疫活性改善用组合物及其方法
CN111122523A (zh) * 2019-12-06 2020-05-08 山西大学 一种快速识别Ag+和Cys的三相输出功能的分子逻辑门及其构建方法
WO2021243932A1 (zh) * 2020-06-03 2021-12-09 江苏靶标生物医药研究所有限公司 一种磷脂酰丝氨酸在制备治疗炎症性肠病药物中的应用
CN111650307A (zh) * 2020-07-13 2020-09-11 重庆医药高等专科学校 一种同时对酒中解热镇痛类药品非法添加物定性定量检测的方法及应用
CN116322669A (zh) * 2020-07-23 2023-06-23 普渡研究基金会 治疗sars-cov-2、其它病毒性疾病和癌症的ohpp配制的氯硝柳胺
CN116209432A (zh) * 2020-08-14 2023-06-02 梅约医学教育与研究基金会 组织消融方法和材料
CN111920824A (zh) * 2020-09-11 2020-11-13 余朝权 一种治疗伤口的中药组合物
CN114246852A (zh) * 2020-09-21 2022-03-29 暨南大学 一种药物组合物在心脑血管疾病中的应用
CN116917267B (zh) * 2021-01-28 2025-08-12 Imd制药公司 包含卡莫司他及氯硝柳胺的共晶、包含其的药物组合物及其制备方法
CN116917267A (zh) * 2021-01-28 2023-10-20 Imd制药公司 包含卡莫司他及氯硝柳胺的共晶、包含其的药物组合物及其制备方法
CN112826795B (zh) * 2021-03-23 2022-08-30 重庆医科大学 一种载汉防己甲素脂质体制剂及其制备方法和应用
CN112826795A (zh) * 2021-03-23 2021-05-25 重庆医科大学 一种载汉防己甲素脂质体制剂及其制备方法和应用
CN114134195B (zh) * 2021-11-03 2024-06-11 南方科技大学 预防前列腺癌的药剂的筛选方法、硝唑尼特在制药中的应用
CN114134195A (zh) * 2021-11-03 2022-03-04 南方科技大学 预防前列腺癌的药剂的筛选方法、硝唑尼特在制药中的应用
CN113908154A (zh) * 2021-11-29 2022-01-11 中国药科大学 硝唑尼特及其体内代谢物替唑尼特在抗银屑病及银屑病样皮肤炎症中的应用
CN114393662A (zh) * 2021-12-21 2022-04-26 凭祥青山中密度纤维板有限公司 一种环保中密度纤维板的制备方法
CN114796135A (zh) * 2022-03-29 2022-07-29 海南久常制药有限公司 一种硫糖铝口服制剂及其制备方法
CN114652734A (zh) * 2022-03-31 2022-06-24 李红梦 一种祛痘的药物组合物及其制备方法
CN114767871A (zh) * 2022-04-19 2022-07-22 中国工程物理研究院机械制造工艺研究所 介孔硅载药体系及制备方法和介孔硅载药
CN114767871B (zh) * 2022-04-19 2023-04-07 中国工程物理研究院机械制造工艺研究所 介孔硅载药体系及制备方法和介孔硅载药
CN117045657A (zh) * 2022-05-12 2023-11-14 广州嘉越医药科技有限公司 一种药物组合及其应用
CN115739028B (zh) * 2022-11-26 2024-04-02 西南政法大学 一种精神活性物质吸附剂及其应用
CN115739028A (zh) * 2022-11-26 2023-03-07 西南政法大学 一种精神活性物质吸附剂及其应用
CN116036289B (zh) * 2023-02-03 2025-05-06 中国药科大学 一种增强铁死亡治疗效果的纳米制剂及其制备方法和应用
CN116036289A (zh) * 2023-02-03 2023-05-02 中国药科大学 一种增强铁死亡治疗效果的纳米制剂及其制备方法和应用
CN116077424A (zh) * 2023-02-17 2023-05-09 重庆大学 一种多功能仿生水凝胶及其制备方法和应用
CN116531366A (zh) * 2023-05-23 2023-08-04 新乡医学院 罗替戈汀的药物新用途
CN117899225A (zh) * 2024-01-19 2024-04-19 芮城绿曼生物药业有限公司 一种增强免疫力的兽用抗菌注射剂、制备方法及应用
CN120204184A (zh) * 2025-02-17 2025-06-27 深圳市第三人民医院(深圳市肝病研究所) 阿米替林和/或其衍生物的应用、结核分枝杆菌抑制剂和药物组合物
CN119700664A (zh) * 2025-02-28 2025-03-28 山东新时代药业有限公司 含有活性成分琥珀酸普芦卡必利的注射液及其制备方法

Also Published As

Publication number Publication date
CL2021000622A1 (es) 2021-10-01
US20210401784A1 (en) 2021-12-30
US10744103B2 (en) 2020-08-18
BR112018004069A2 (pt) 2021-07-13
US10849867B2 (en) 2020-12-01
PE20181295A1 (es) 2018-08-07
US20240074995A1 (en) 2024-03-07
US20200268694A1 (en) 2020-08-27
KR20180080189A (ko) 2018-07-11
HK1258048A1 (zh) 2019-11-01
CO2018003465A2 (es) 2018-08-31
US20220000812A1 (en) 2022-01-06
WO2017040864A1 (en) 2017-03-09
AU2016315852A1 (en) 2018-03-22
US20170056347A1 (en) 2017-03-02
US11793777B2 (en) 2023-10-24
US20200147012A1 (en) 2020-05-14
TN2018000069A1 (en) 2019-07-08
US20200276140A1 (en) 2020-09-03
EP3344274A4 (en) 2019-05-22
EA201890618A1 (ru) 2018-10-31
JP7189983B2 (ja) 2022-12-14
JP2021098727A (ja) 2021-07-01
US20200147013A1 (en) 2020-05-14
IL257801A (en) 2018-04-30
MX2018002586A (es) 2020-11-24
PH12018500448A1 (en) 2018-09-24
SG10201914118SA (en) 2020-02-27
MX2023014409A (es) 2023-12-13
AU2016315852B2 (en) 2023-06-15
EP3344274A1 (en) 2018-07-11
US20200197339A1 (en) 2020-06-25
CR20180185A (es) 2018-12-06
US10799468B2 (en) 2020-10-13
MX2022014310A (es) 2022-12-07
US20190298670A1 (en) 2019-10-03
US20200197340A1 (en) 2020-06-25
US10905666B2 (en) 2021-02-02
CA2997136A1 (en) 2017-03-09
US10292951B2 (en) 2019-05-21
AU2023203354A1 (en) 2023-07-06
JP2018529762A (ja) 2018-10-11
JP6955648B2 (ja) 2021-10-27
US10912746B2 (en) 2021-02-09
UA125747C2 (uk) 2022-06-01
US10772854B2 (en) 2020-09-15

Similar Documents

Publication Publication Date Title
US20240074995A1 (en) Methods and compositions for treating conditions associated with an abnormal inflammatory responses
US11564896B2 (en) Methods of treatment
US20210114973A1 (en) Pharmaceutical formulations
WO2021188564A1 (en) Methods of treating covid-19 with a niclosamide compound
US20230102999A1 (en) Deuterated niclosamide
WO2023118074A1 (en) Compressible and free flowing co-processed mesoporous silica

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: G.D. Glick

Inventor after: L. Francher

Inventor after: G. Santos

Inventor before: G.D. Glick

Inventor before: L. Francher

CB03 Change of inventor or designer information